Tonix Pharmaceuticals Holding Corp. — Q2 2012 Form 10-Q
Business context and period: Development-stage specialty pharmaceutical company focused on central nervous system drug candidates. This unaudited report covers the quarter and six months ended June 30, 2012; the company reported no commercial products or revenue.
Financial results and liquidity
| Metric | Q2 2012 | Six months ended June 30, 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $827,788 | $1,225,416 |
| General and administrative expense | $1,023,150 | $1,785,887 |
| Operating loss | $1,850,939 | $3,011,303 |
| Net loss | $3,073,690 | $5,088,678 |
| Net loss per share, basic and diluted | $0.09 | $0.15 |
Gross margin is not applicable because the company had no revenue or cost of goods sold. Six-month operating cash use was $2,907,427; investing cash use was $33,859; financing provided $4,237,894. Cash was $1,337,731 at June 30, versus $41,123 at December 31, 2011. Working capital was $554,939. Total liabilities were $810,849, including $782,792 current liabilities; convertible debentures were paid or exchanged and none remained outstanding. Restricted cash of $60,222 collateralized a lease letter of credit.
Changes versus prior comparable periods
- Q2 net loss increased from $355,810 in Q2 2011; six-month net loss rose from $869,466 in 2011.
- Six-month R&D expense increased 760% to $1.23 million, principally due to greater TNX-102 development activity. Six-month G&A rose 146% to $1.79 million, reflecting staffing and compensation, professional and public-company costs, travel, and related-party consulting.
- Six-month operating cash use increased from $612,364 in 2011. Cash increased primarily following January and March equity-and-warrant financings that generated $4,387,894 net proceeds; $150,000 of debentures was repaid.
- Common shares outstanding increased to 34,278,432 from 27,066,667 at year-end. The company also had 7,390,292 warrants outstanding and granted 3,500,000 options in May.
Outlook, risks, and notable items
- Management planned a pivotal TNX-102 sublingual fibromyalgia efficacy trial in Q1 2013 and a TNX-105 PTSD proof-of-concept trial in 2013, subject to obtaining necessary funds. It expected R&D costs to increase significantly over the next 12–24 months and expected operating losses to continue.
- Management stated existing cash was expected to fund operating expenses and capital equipment for only the next three months. The company said additional capital was required and warned that unavailable or unfavorable financing could force it to reduce or discontinue programs, delay development, or relinquish product rights.
- The filing states that recurring losses, negative operating cash flows, lack of products and the need for further financing raise substantial doubt about the company’s ability to continue as a going concern. There were no existing commitments to fund future operations.
- The $1,177,026 six-month loss from the change in fair value of warrants was a noncash charge. After registration effectiveness in June, warrant reset provisions expired and the warrant liability was reclassified to equity. Six-month interest and other financing costs were $900,349, largely reflecting financing-related charges and noncash consideration.
- Related-party consulting arrangements included annual fees of $96,000 to L&L Technologies and, from February 2012, $250,000 to Lederman & Co.; six-month expenses under the disclosed agreements totaled $138,750. The filing reported no material legal proceedings or defaults on senior securities.
Important facts for investors to verify
- Whether subsequent financing was obtained and how it affected liquidity, dilution, and the stated three-month cash runway.
- Progress, timing, funding, and results of the planned TNX-102 and TNX-105 clinical trials, including regulatory requirements and potential delays.
- Potential dilution from outstanding warrants, options, and future capital raises; confirm exercise and registration terms.
- Whether reported warrant accounting, financing costs, and related-party expenses are understood in light of their noncash and contractual components.
- Whether the company’s going-concern uncertainty and internal controls or reporting circumstances changed after June 30, 2012.